This is a summary of the European public assessment report (EPAR) for Oslif Breezhaler. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Oslif Breezhaler. For practical information about using Oslif Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Therapeutic Area (MeSH)
ATC Code
R03AC18
ATC Item
indacaterol
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| indacaterol maleate | N/A | 茚达特罗 |
EMA Name
Oslif Breezhaler
Medicine Name
Oslif Breezhaler
Aliases
N/ANo risk management plan link.
